Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» CureVac
CureVac
CureVac’s COVID vaccine patent battle with Pfizer, BioNTech heads South
CureVac’s COVID vaccine patent battle with Pfizer, BioNTech heads South
Medical Marketing and Media
CureVac
COVID-19
vaccines
Pfizer
BioNTech
patents legal
Flag link:
Orbital shows 2023’s venture funding scene is far from stratospheric
Orbital shows 2023’s venture funding scene is far from stratospheric
EP Vantage
RNA
funding
venture capital
Altos Labs
CureVac
EQRx
Hasten Biopharmaceutic
Orbital Therapeutics
Sana Biotechnology
Suzhou Abogen Biosciences
TORL BioTherapeutics
Flag link:
GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine
GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine
Clinical Trials Arena
GSK
CureVac
vaccines
MRNA
Flu
Flag link:
After 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults
After 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults
Fierce Biotech
CureVac
clinical trials
MRNA
vaccines
COVID-19
Flu
GSK
Flag link:
CureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17%
CureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17%
Fierce Biotech
CureVac
GSK
MRNA
vaccines
COVID-19
clinical trials
Flag link:
CureVac rethinks lead cancer program after posting PD-1 data, limiting future studies to mRNA vaccine combos
CureVac rethinks lead cancer program after posting PD-1 data, limiting future studies to mRNA vaccine combos
Fierce Biotech
CureVac
vaccines
CV8102
MRNA
cancer
Flag link:
Few safe havens surface in another down quarter for biopharma
Few safe havens surface in another down quarter for biopharma
EP Vantage
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Flag link:
CureVac begins Phase I Omicron-targeting Covid-19 vaccine trial
CureVac begins Phase I Omicron-targeting Covid-19 vaccine trial
Clinical Trials Arena
CureVac
clinical trials
MRNA
CV0501
boosters
COVID-19
Flag link:
Pfizer and BioNTech Push Hard on Omicron-Specific Vaccine While Fending Off Lawsuits
Pfizer and BioNTech Push Hard on Omicron-Specific Vaccine While Fending Off Lawsuits
BioSpace
Pfizer
BioNTech
COVID-19
vaccines
boosters
patents
CureVac
Flag link:
Pfizer, BioNTech rebuff CureVac's 'groundless' patent infringement claims against COVID-19 shot Comirnaty
Pfizer, BioNTech rebuff CureVac's 'groundless' patent infringement claims against COVID-19 shot Comirnaty
Fierce Pharma
Pfizer
BioNTech
COVID-19
CureVac
vaccines
patents
Flag link:
After its own vaccine flop, CureVac sues Pfizer partner BioNTech for patent infringement
After its own vaccine flop, CureVac sues Pfizer partner BioNTech for patent infringement
Fierce Pharma
COVID-19
CureVac
BioNTech
patents
vaccines
Flag link:
CureVac increases focus on cancer vaccine development
CureVac increases focus on cancer vaccine development
Biopharma Reporter
CureVac
myNEO
vaccines
cancer
MRNA
Flag link:
With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech
With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech
Fierce Biotech
CureVac
COVID-19
vaccines
earnings
Flag link:
Opportunities arise for once-spurned partners
Opportunities arise for once-spurned partners
EP Vantage
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Flag link:
GlaxoSmithKline, CureVac and BioNTech clinch German pandemic preparedness contracts
GlaxoSmithKline, CureVac and BioNTech clinch German pandemic preparedness contracts
Fierce Pharma
GSK
BioNTech
CureVac
Germany
pandemic
Flag link:
CureVac and GSK try again with COVID-19 vaccine
CureVac and GSK try again with COVID-19 vaccine
Pharmaforum
GSK
CureVac
vaccines
COVID-19
MRNA
Flag link:
BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report
BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report
Fierce Pharma
Germany
BioNTech
CureVac
GSK
vaccines
Flag link:
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
Yahoo Finance
CureVac
MRNA
vaccines
COVID-19
Flag link:
End-of-Year Restructuring Means Layoffs for These Companies
End-of-Year Restructuring Means Layoffs for These Companies
BioSpace
restructuring
Rigel Pharmaceuticals
Zymergen
Esperion Therapeutics
Amarin
Theravance
Sanofi
Acorda Therapeutics
CureVac
Ziopharm Oncology
Flag link:
Bayer breaks off Covid-19 vaccine manufacturing pact as CureVac pivots to second-gen work — report
Bayer breaks off Covid-19 vaccine manufacturing pact as CureVac pivots to second-gen work — report
Endpoints
CureVac
Bayer
vaccines
COVID-19
MRNA
drug manufacturing
Flag link:
Pages
1
2
3
4
next ›
last »